Previous 10 | Next 10 |
Gainers: Nano Dimension NNDM +272% . More news on: ShiftPixy, Inc., Mercurity Fintech Holding Inc., Iterum Therapeutics plc, Stocks on the move, , Read more ...
58% complete response rate reported for patients with relapsed/refractory MCL, with a median follow-up of 8.3 months 100% progression-free survival reported for patients with CLL, with a median follow-up of 12.8 months Cirmtuzumab continued to be well tolerated in this trial ...
Oncternal Therapeutics, Inc. (ONCT) Q1 2020 Earnings Conference Call May 7, 2020, 05:00 PM ET Company Participants Richard Vincent - CFO Jim Breitmeyer - President and CEO Frank Hsu - Chief Medical Officer Conference Call Participants Hartaj Singh - Oppenheimer Carl Byrne...
Oncternal Therapeutics (NASDAQ: ONCT ): Q1 GAAP EPS of -$0.31. More news on: Oncternal Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
- Deep clinical responses reported for two of seven patients with relapsed/refractory Ewing sarcoma treated with the recommended Phase 2 dose of TK216 in ongoing Phase 1 clinical trial - 50% complete response rate reported in patients with relapsed/refractory MCL in ongoing Phase 1/2 ...
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2020 financial results after the U.S. financial markets close on Thursday, May 7, 2020. Oncternal...
Oncternal Therapeutics, Inc. (ONCT) Q4 2019 Results Conference Call March 16, 2020 04:30 PM ET Company Participants Richard Vincent - CFO Dr. Jim Breitmeyer - President and CEO Dr. Frank Hsu - Chief Medical Officer Conference Call Participants Hartaj Singh - Oppenheimer M...
Oncternal Therapeutics (NASDAQ: ONCT ): Q4 GAAP EPS of -$0.27. More news on: Oncternal Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
- Steady progress of clinical programs in four indications: MCL, Ewing sarcoma, breast cancer, and CLL - Cirmtuzumab in combination with ibrutinib demonstrated a 50% CR rate and 83% best ORR in patients with relapsed/refractory MCL in an interim analysis from an ongoing Phase 1/2 cl...
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report its fourth quarter and full year 2019 financial results on March 16, 2020. Oncternal’s management will hos...
News, Short Squeeze, Breakout and More Instantly...
Oncternal Therapeutics Inc. Company Name:
ONCT Stock Symbol:
NASDAQ Market:
Oncternal Therapeutics Inc. Website:
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2024 financial results after the U.S. financial markets c...
2024-07-26 13:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the sixth dose cohort of its Pha...